Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study . Ann Med Res . 2021;27(1):0029-0033. Accessed April 9, 2025. http://annalsmedres.org/index.php/aomr/article/view/591